Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Retained Earnings (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Retained Earnings for 4 consecutive years, with -$362.6 million as the latest value for Q4 2025.

  • Quarterly Retained Earnings fell 697367.31% to -$362.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$362.6 million through Dec 2025, down 697367.31% year-over-year, with the annual reading at -$362.6 million for FY2025, 697367.31% down from the prior year.
  • Retained Earnings for Q4 2025 was -$362.6 million at Orchestra BioMed Holdings, down from $45000.0 in the prior quarter.
  • The five-year high for Retained Earnings was $52000.0 in Q4 2024, with the low at -$362.6 million in Q4 2025.
  • Average Retained Earnings over 4 years is -$106.5 million, with a median of -$4.8 million recorded in 2022.
  • Peak annual rise in Retained Earnings hit 562.5% in 2025, while the deepest fall reached 1512943.48% in 2025.
  • Over 4 years, Retained Earnings stood at -$199.7 million in 2022, then decreased by 24.59% to -$248.9 million in 2023, then skyrocketed by 100.02% to $52000.0 in 2024, then tumbled by 697367.31% to -$362.6 million in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$362.6 million, $45000.0, and -$348.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.